Bioenergetic medicine

British Journal of Pharmacology

Volumn 171, Issue 8, 2014, Pages 1854-1869

  Swerdlow, Russell H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; cancer; glycolysis; law of mass action; mitochondria; neurodegeneration

Indexed keywords

MITOCHONDRIAL DNA;

BIOENERGETIC MEDICINE; BIOENERGY; BIOMEDICINE; CITRIC ACID CYCLE; COPY NUMBER VARIATION; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY EXPENDITURE; ENERGY METABOLISM; FATTY ACID METABOLISM; FEASIBILITY STUDY; GENE MUTATION; GLYCOLYSIS; HUMAN; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STUDY DESIGN; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; METABOLISM; MITOCHONDRIAL DISEASES; MOLECULARLY TARGETED THERAPY; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; PROCEDURES;

ANIMALS; ENERGY METABOLISM; HUMANS; MITOCHONDRIAL DISEASES; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES;

EID: 84897409736     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12394     Document Type: Review

References (189)

1. Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270-279.
2. Almeida A, Bolanos JP, Moncada S, (2010). E3 ubiquitin ligase APC/C-Cdh1 accounts for the Warburg effect by linking glycolysis to cell proliferation. Proc Natl Acad Sci U S A 107: 738-741.
3. Asai M, Fujikawa A, Noda A, Miyoshi S, Matsuoka N, Nishimura S, (2009). Donepezil- and scopolamine-induced rCMRglu changes assessed by PET in conscious rhesus monkeys. Ann Nucl Med 23: 877-882.
4. Banerjee R, Beal MF, Thomas B, (2010). Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci 33: 541-549.
5. Barrientos A, Casademont J, Cardellach F, Ardite E, Estivill X, Urbano-Marquez A, et al. (1997a). Qualitative and quantitative changes in skeletal muscle mtDNA and expression of mitochondrial-encoded genes in the human aging process. Biochem Mol Med 62: 165-171.
6. Barrientos A, Casademont J, Cardellach F, Estivill X, Urbano-Marquez A, Nunes V, (1997b). Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Brain Res Mol Brain Res 52: 284-289.
7. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB, (1996). Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 7: 1397-1400.
8. Bergamini E, Cavallini G, Donati A, Gori Z, (2003). The anti-ageing effects of caloric restriction may involve stimulation of macroautophagy and lysosomal degradation, and can be intensified pharmacologically. Biomed Pharmacother 57: 203-208.
9. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT, (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306.
10. Betts J, Lightowlers RN, Turnbull DM, (2004). Neuropathological aspects of mitochondrial DNA disease. Neurochem Res 29: 505-511.
11. Blass JP, Gibson GE, (2006). Correlations of disability and biologic alterations in Alzheimer brain and test of significance by a therapeutic trial in humans. J Alzheimers Dis 9: 207-218.
12. Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J, (2004). Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 25: 495-520.
13. Boveris A, Navarro A, (2008). Brain mitochondrial dysfunction in aging. IUBMB Life 60: 308-314.
14. Bratic A, Larsson NG, (2013). The role of mitochondria in aging. J Clin Invest 123: 951-957.
15. Brown GC, (1999). Nitric oxide and mitochondrial respiration. Biochim Biophys Acta 1411: 351-369.
16. Canto C, Auwerx J, (2009a). PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20: 98-105.
17. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. (2009b). AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458: 1056-1060.
18. Cardenas C, Miller RA, Smith I, Bui T, Molgo J, Muller M, et al. (2010). Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell 142: 270-283.
19. Cardoso SM, Santana I, Swerdlow RH, Oliveira CR, (2004). Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 89: 1417-1426.
20. Chan DC, (2006). Mitochondria: dynamic organelles in disease, aging, and development. Cell 125: 1241-1252.
21. Chaturvedi RK, Beal MF, (2013). Mitochondrial diseases of the brain. Free Radic Biol Med 63: 1-29.
22. Chen H, Chan DC, (2009). Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 18: R169-R176.
23. Chetelat G, Landeau B, Salmon E, Yakushev I, Bahri MA, Mezenge F, et al. (2013). Relationships between brain metabolism decrease in normal aging and changes in structural and functional connectivity. Neuroimage 76: 167-177.
24. Clark JB, (1998). N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 20: 271-276.
25. Cookson MR, (2012). Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. Cold Spring Harb Perspect Med 2: a009415.
26. Cooper JM, Schapira AH, (2007). Friedreich's ataxia: coenzyme Q10 and vitamin E therapy. Mitochondrion 7 (Suppl): S127-S135.
27. Cotman CW, Berchtold NC, (2002). Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 25: 295-301.
28. Crabtree HG, (1928). The carbohydrate metabolism of certain pathological overgrowths. Biochem J 22: 1289-1298.
29. Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, et al. (2011). The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 17: 1652-1656.
30. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D, (2006). Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127: 59-69.
31. De Santi S, de Leon MJ, Convit A, Tarshish C, Rusinek H, Tsui WH, et al. (1995). Age-related changes in brain: II Positron emission tomography of frontal and temporal lobe glucose metabolism in normal subjects. Psychiatr Q 66: 357-370.
32. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH, (2007). Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 6: 878-886.
33. Dimauro S, (2013). Mitochondrial encephalomyopathies-fifty years on: the Robert Wartenberg Lecture. Neurology 81: 281-291.
34. DiMauro S, Schon EA, (2008). Mitochondrial disorders in the nervous system. Annu Rev Neurosci 31: 91-123.
35. Dorsey ER, Albin RL, Blindauer KA, Chiu E, Colcher A, Corey-Bloom J, et al. (2013). A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. JAMA Neurology 70: 25-33.
36. Dumont M, Lin MT, Beal MF, (2010). Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. J Alzheimers Dis 20 (Suppl. 2): S633-S643.
37. E L, Lu J, Burns JM, Swerdlow RH, (2013a). Effect of exercise on mouse liver and brain bioenergetic infrastructures. Exp Physiol 98: 207-219.
38. E L, Lu J, Selfridge JE, Burns JM, Swerdlow RH, (2013b). Lactate administration reproduces specific brain and liver exercise-related changes. J Neurochem. Epub ahead of print.
39. Eckel RH, Grundy SM, Zimmet PZ, (2005). The metabolic syndrome. Lancet 365: 1415-1428.
40. Esteves AR, Domingues AF, Ferreira IL, Januario C, Swerdlow RH, Oliveira CR, et al. (2008). Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. Mitochondrion 8: 219-228.
41. Faissner A, Pyka M, Geissler M, Sobik T, Frischknecht R, Gundelfinger ED, et al. (2010). Contributions of astrocytes to synapse formation and maturation-potential functions of the perisynaptic extracellular matrix. Brain Res Rev 63: 26-38.
42. Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, et al. (1996). Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 11: 321-323.
43. Ferguson EC, Rathmell JC, (2008). New roles for pyruvate kinase M2: working out the Warburg effect. Trends Biochem Sci 33: 359-362.
44. Feron O, (2009). Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 92: 329-333.
45. Filosto M, Tomelleri G, Tonin P, Scarpelli M, Vattemi G, Rizzuto N, et al. (2007). Neuropathology of mitochondrial diseases. Biosci Rep 27: 23-30.
46. Finkel T, (2003). Oxidant signals and oxidative stress. Curr Opin Cell Biol 15: 247-254.
47. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro G, (1983). Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 33: 961-965.
48. Frackowiak RS, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, et al. (1981). Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 104: 753-778.
49. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, et al. (1983). Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr 7: 590-598.
50. Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J, Yonekura Y, et al. (1994). Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J Nucl Med 35: 1-6.
51. Gibson GE, Starkov A, Blass JP, Ratan RR, Beal MF, (2010). Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim Biophys Acta 1802: 122-134.
52. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. (2007). Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6: 1045-1053.
53. Greco T, Fiskum G, (2010). Neuroprotection through stimulation of mitochondrial antioxidant protein expression. J Alzheimers Dis 20 (Suppl. 2): S427-S437.
54. Gu M, Cooper JM, Taanman JW, Schapira AH, (1998). Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 44: 177-186.
55. Guarente L, (2007). Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 72: 483-488.
56. Gutzmann H, Hadler D, (1998). Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl 54: 301-310.
57. Handschin C, Spiegelman BM, (2006). Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27: 728-735.
58. Hardie DG, (2007). AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785.
59. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460: 392-395.
60. Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, Turner C, et al. (2005). Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 62: 621-626.
61. Hartman AL, Gasior M, Vining EP, Rogawski MA, (2007). The neuropharmacology of the ketogenic diet. Pediatr Neurol 36: 281-292.
62. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC, (2009). Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 6: 31.
63. Henigsberg N, Kalember P, Hrabac P, Rados M, Bajs M, Kovavic Z, et al. (2011). 1-H MRS changes in dorsolateral prefrontal cortex after donepezil treatment in patients with mild to moderate Alzheimer's disease. Coll Antropol 35 (Suppl. 1): 159-162.
64. Hepple RT, (2009). Why eating less keeps mitochondria working in aged skeletal muscle. Exerc Sport Sci Rev 37: 23-28.
65. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. (2001). Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21: 3017-3023.
66. Holloszy JO, (1975). Adaptation of skeletal muscle to endurance exercise. Med Sci Sports 7: 155-164.
67. Howell N, (1998). Leber hereditary optic neuropathy: respiratory chain dysfunction and degeneration of the optic nerve. Vision Res 38: 1495-1504.
68. Hudson G, Nalls M, Evans JR, Breen DP, Winder-Rhodes S, Morrison KE, et al. (2013). Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology 80: 2042-2048.
69. Ihara Y, Namba R, Kuroda S, Sato T, Shirabe T, (1989). Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. J Neurol Sci 90: 263-271.
70. Jahani-Asl A, Cheung EC, Neuspiel M, MacLaurin JG, Fortin A, Park DS, et al. (2007). Mitofusin 2 protects cerebellar granule neurons against injury-induced cell death. J Biol Chem 282: 23788-23798.
71. Jessen F, Traeber F, Freymann K, Maier W, Schild HH, Block W, (2006). Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 67: 528-530.
72. Joffe GT, Parks JK, Parker WD, Jr, (1998). Secondary inhibition of 2-ketoglutarate dehydrogenase complex by MPTP. Neuroreport 9: 2781-2783.
73. Jones RW, (2010). Dimebon disappointment. Alzheimers Res Ther 2: 25.
74. Jung CH, Ro SH, Cao J, Otto NM, Kim DH, (2010). mTOR regulation of autophagy. FEBS Lett 584: 1287-1295.
75. Kalpouzos G, Chetelat G, Baron JC, Landeau B, Mevel K, Godeau C, et al. (2009). Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging 30: 112-124.
76. Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, et al. (2010). With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 11: 453-465.
77. Keller C, Kadir A, Forsberg A, Porras O, Nordberg A, (2011). Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. J Alzheimers Dis 24: 109-123.
78. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, et al. (2001). Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 276: 4588-4596.
79. Koopman WJ, Willems PH, Smeitink JA, (2012). Monogenic mitochondrial disorders. N Engl J Med 366: 1132-1141.
80. Korde AS, Pettigrew LC, Craddock SD, Maragos WF, (2005). The mitochondrial uncoupler 2,4-dinitrophenol attenuates tissue damage and improves mitochondrial homeostasis following transient focal cerebral ischemia. J Neurochem 94: 1676-1684.
81. Kossoff EH, Zupec-Kania BA, Rho JM, (2009). Ketogenic diets: an update for child neurologists. J Child Neurol 24: 979-988.
82. Krebs HA, (1972). The Pasteur effect and the relations between respiration and fermentation. Essays Biochem 8: 1-34.
83. Krikorian R, Shidler MD, Dangelo K, Couch SC, Benoit SC, Clegg DJ, (2012). Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol Aging 33: e419-e427.
84. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, et al. (2003). Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160: 2003-2011.
85. Lambert AJ, Wang B, Yardley J, Edwards J, Merry BJ, (2004). The effect of aging and caloric restriction on mitochondrial protein density and oxygen consumption. Exp Gerontol 39: 289-295.
86. Langston JW, Ballard P, Tetrud JW, Irwin I, (1983). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980.
87. Lu J, E L, Roy N, Hutfles L, Selfridge E, Funk E, et al. (2013). Effect of cholinergic signaling on neuronal cell bioenergetics. J Alzheimers Dis 33: 1135-1146.
88. Lucia A, Nogales-Gadea G, Perez M, Martin MA, Andreu AL, Arenas J, (2008). McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol 4: 568-577.
89. Luft R, (1994). The development of mitochondrial medicine. Proc Natl Acad Sci U S A 91: 8731-8738.
90. Maassen JA, Janssen GM, t Hart LM, (2005). Molecular mechanisms of mitochondrial diabetes (MIDD). Ann Med 37: 213-221.
91. Maassen JA, t Hart LM, Ouwens DM, (2007). Lessons that can be learned from patients with diabetogenic mutations in mitochondrial DNA: implications for common type 2 diabetes. Curr Opin Clin Nutr Metab Care 10: 693-697.
92. Magistretti PJ, Pellerin L, (1999). Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci 354: 1155-1163.
93. Mancuso M, Orsucci D, Volpi L, Calsolaro V, Siciliano G, (2010). Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets 11: 111-121.
94. Manczak M, Jung Y, Park BS, Partovi D, Reddy PH, (2005). Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. J Neurochem 92: 494-504.
95. Manczak M, Calkins MJ, Reddy PH, (2011). Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum Mol Genet 20: 2495-2509.
96. Marano CM, Workman CI, Kramer E, Hermann CR, Ma Y, Dhawan V, et al. (2013). Longitudinal studies of cerebral glucose metabolism in late-life depression and normal aging. Int J Geriatr Psychiatry 28: 417-423.
97. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S, (2003). Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60: 1676-1679.
98. Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR, (2012). Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol 259: 284-291.
99. Modrego PJ, (2006). The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques. Curr Med Chem 13: 3417-3424.
100. Morino K, Petersen KF, Shulman GI, (2006). Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55 (Suppl. 2): S9-S15.
101. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. (2001). Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58: 397-405.
102. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ, (2010). Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis 20: 843-854.
103. Musumeci O, Naini A, Slonim AE, Skavin N, Hadjigeorgiou GL, Krawiecki N, et al. (2001). Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 56: 849-855.
104. Navarro A, Boveris A, (2007). The mitochondrial energy transduction system and the aging process. Am J Physiol Cell Physiol 292: C670-C686.
105. Navarro A, Gomez C, Lopez-Cepero JM, Boveris A, (2004). Beneficial effects of moderate exercise on mice aging: survival, behavior, oxidative stress, and mitochondrial electron transfer. Am J Physiol Regul Integr Comp Physiol 286: R505-R511.
106. Newman LA, Korol DL, Gold PE, (2011). Lactate produced by glycogenolysis in astrocytes regulates memory processing. PLoS ONE 6: e28427.
107. Nicklas WJ, Vyas I, Heikkila RE, (1985). Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36: 2503-2508.
108. Onyango IG, Lu J, Rodova M, Lezi E, Crafter AB, Swerdlow RH, (2010). Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim Biophys Acta 1802: 228-234.
109. Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF, Jr, (1967). Brain metabolism during fasting. J Clin Invest 46: 1589-1595.
110. Pandolfo M, (2008). Friedreich ataxia. Arch Neurol 65: 1296-1303.
111. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, et al. (2002). Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5: 731-736.
112. Parker WD, Jr, Parks JK, (1995). Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology 45: 482-486.
113. Parker WD, Jr, Swerdlow RH, (1998). Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genet 62: 758-762.
114. Parker WD, Jr, Boyson SJ, Parks JK, (1989). Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719-723.
115. Parker WD, Jr, Filley CM, Parks JK, (1990). Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40: 1302-1303.
116. Patel TB, Clark JB, (1979). Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 184: 539-546.
117. Patti ME, Corvera S, (2010). The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 31: 364-395.
118. Pellerin L, Magistretti PJ, (1994). Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A 91: 10625-10629.
119. Pellerin L, Magistretti PJ, (2003). Food for thought: challenging the dogmas. J Cereb Blood Flow Metab 23: 1282-1286.
120. Pellerin L, Magistretti PJ, (2004). Neuroenergetics: calling upon astrocytes to satisfy hungry neurons. Neuroscientist 10: 53-62.
121. Perea G, Navarrete M, Araque A, (2009). Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 32: 421-431.
122. Perez-Pinzon MA, Stetler RA, Fiskum G, (2012). Novel mitochondrial targets for neuroprotection. J Cereb Blood Flow Metab 32: 1362-1376.
123. Pfeffer G, Horvath R, Klopstock T, Mootha VK, Suomalainen A, Koene S, et al. (2013). New treatments for mitochondrial disease-no time to drop our standards. Nat Rev Neurol 9: 474-481.
124. Pfeuffer J, Tkac I, Choi IY, Merkle H, Ugurbil K, Garwood M, et al. (1999). Localized in vivo 1H NMR detection of neurotransmitter labeling in rat brain during infusion of [1-13C] d-glucose. Magn Reson Med 41: 1077-1083.
125. Pierre K, Pellerin L, (2005). Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J Neurochem 94: 1-14.
126. van Praag H, Shubert T, Zhao C, Gage FH, (2005). Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci 25: 8680-8685.
127. Quinzii CM, DiMauro S, Hirano M, (2007). Human coenzyme Q10 deficiency. Neurochem Res 32: 723-727.
128. Rabinowitz JD, White E, (2010). Autophagy and metabolism. Science 330: 1344-1348.
129. Rains JL, Jain SK, (2011). Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med 50: 567-575.
130. Reddy PH, (2006). Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol 2006: 31372.
131. Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, et al. (2004). Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 25: 311-314.
132. Ren J, Pulakat L, Whaley-Connell A, Sowers JR, (2010). Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med 88: 993-1001.
133. Riobo NA, Clementi E, Melani M, Boveris A, Cadenas E, Moncada S, et al. (2001). Nitric oxide inhibits mitochondrial NADH:ubiquinone reductase activity through peroxynitrite formation. Biochem J 359: 139-145.
134. Ristow M, Zarse K, Oberbach A, Kloting N, Birringer M, Kiehntopf M, et al. (2009). Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci U S A 106: 8665-8670.
135. Rojo A, Campos Y, Sanchez JM, Bonaventura I, Aguilar M, Garcia A, et al. (2006). NARP-MILS syndrome caused by 8993 T>G mitochondrial DNA mutation: a clinical, genetic and neuropathological study. Acta Neuropathol 111: 610-616.
136. Sarbassov DD, Ali SM, Sabatini DM, (2005). Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596-603.
137. Scaglia F, Northrop JL, (2006). The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options. CNS Drugs 20: 443-464.
138. Scarpulla RC, (2008). Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 88: 611-638.
139. Schieke SM, Finkel T, (2006). Mitochondrial signaling, TOR, and life span. Biol Chem 387: 1357-1361.
140. Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, Ristow M, (2007). Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab 6: 280-293.
141. Semenza GL, (2012). Hypoxia-inducible factors in physiology and medicine. Cell 148: 399-408.
142. Shigenaga MK, Hagen TM, Ames BN, (1994). Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A 91: 10771-10778.
143. Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC, (1990). Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 61: 931-937.
144. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. (2002). Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59: 1541-1550.
145. Silva DF, Selfridge JE, Lu J, E L, Roy N, Hutfles L, et al. (2013). Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines. Hum Mol Genet 22: 3931-3946.
146. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. (2001). Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286: 2120-2127.
147. Sims NR, Finegan JM, Blass JP, Bowen DM, Neary D, (1987). Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res 436: 30-38.
148. Srivastava S, Diaz F, Iommarini L, Aure K, Lombes A, Moraes CT, (2009). PGC-1alpha/beta induced expression partially compensates for respiratory chain defects in cells from patients with mitochondrial disorders. Hum Mol Genet 18: 1805-1812.
149. Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM, et al. (2008). Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 23: 942-949.
150. Steiner JL, Murphy EA, McClellan JL, Carmichael MD, Davis JM, (2011). Exercise training increases mitochondrial biogenesis in the brain. J Appl Physiol 111: 1066-1071.
151. Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, et al. (2007). Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 64: 938-944.
152. Sudarsanam S, Johnson DE, (2010). Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel 13: 31-40.
153. Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, et al. (2011). Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 144: 810-823.
154. Swerdlow R, Marcus DM, Landman J, Harooni M, Freedman ML, (1989). Brain glucose and ketone body metabolism in patients with Alzheimer's disease. Clin Res 37: 461A.
155. Swerdlow RH, (2007). Treating neurodegeneration by modifying mitochondria: potential solutions to a 'complex' problem. Antioxid Redox Signal 9: 1591-1603.
156. Swerdlow RH, (2009a). Mitochondrial medicine and the neurodegenerative mitochondriopathies. Pharmaceuticals 2: 150-167.
157. Swerdlow RH, (2009b). The neurodegenerative mitochondriopathies. J Alzheimers Dis 17: 737-751.
158. Swerdlow RH, (2011a). Brain aging, Alzheimer's disease, and mitochondria. Biochim Biophys Acta 1812: 1630-1639.
159. Swerdlow RH, (2011b). Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr Pharm Des 17: 3356-3373.
160. Swerdlow RH, (2012a). Alzheimer's disease pathologic cascades: who comes first, what drives what. Neurotox Res 22: 182-194.
161. Swerdlow RH, (2012b). Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid Redox Signal 16: 1434-1455.
162. Swerdlow RH, (2012c). Does mitochondrial DNA play a role in Parkinson's disease? A review of cybrid and other supportive evidence. Antioxid Redox Signal 16: 950-964.
163. Swerdlow RH, Khan SM, (2004). A 'mitochondrial cascade hypothesis' for sporadic Alzheimer's disease. Med Hypotheses 63: 8-20.
164. Swerdlow RH, Khan SM, (2009). The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp Neurol 218: 308-315.
165. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, et al. (1996). Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40: 663-671.
166. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP, Jr, et al. (1997). Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 49: 918-925.
167. Swerdlow RH, Burns JM, Khan SM, (2010). The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 20 (Suppl. 2): S265-S279.
168. Swerdlow RH, E L, Aires D, Lu J, (2013). Glycolysis-respiration relationships in a neuroblastoma cell line. Biochim Biophys Acta 1830: 2891-2898.
169. Tadaishi M, Miura S, Kai Y, Kawasaki E, Koshinaka K, Kawanaka K, et al. (2011). Effect of exercise intensity and AICAR on isoform-specific expressions of murine skeletal muscle PGC-1alpha mRNA: a role of beta(2)-adrenergic receptor activation. Am J Physiol Endocrinol Metab 300: E341-E349.
170. Tan EK, Skipper LM, (2007). Pathogenic mutations in Parkinson disease. Hum Mutat 28: 641-653.
171. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, et al. (2003). Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 61: 1498-1502.
172. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, et al. (2003). Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 11: 169-177.
173. Vander Heiden MG, Cantley LC, Thompson CB, (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
174. Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield SB, (2005). Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology 64: 728-730.
175. Villalba JM, Parrado C, Santos-Gonzalez M, Alcain FJ, (2010). Therapeutic use of coenzyme Q10 and coenzyme Q10-related compounds and formulations. Expert Opin Investig Drugs 19: 535-554.
176. Viollet B, Guigas B, Leclerc J, Hebrard S, Lantier L, Mounier R, et al. (2009). AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) 196: 81-98.
177. Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, et al. (2009). Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 29: 9090-9103.
178. Warburg O, (1956). On the origin of cancer cells. Science 123: 309-314.
179. Wenz T, Williams SL, Bacman SR, Moraes CT, (2010). Emerging therapeutic approaches to mitochondrial diseases. Dev Disabil Res Rev 16: 219-229.
180. Wenz T, Wang X, Marini M, Moraes CT, (2011). A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations. J Cell Mol Med 15: 2317-2325.
181. Weyer G, Babej-Dolle RM, Hadler D, Hofmann S, Herrmann WM, (1997). A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 36: 73-82.
182. Williamson JR, Jones EA, (1964). Inhibition of glycoysis by pyruvate in relation to the accumulation of citric acid cycle intermediates in the perfused rat heart. Nature 203: 1171-1173.
183. Willis MW, Ketter TA, Kimbrell TA, George MS, Herscovitch P, Danielson AL, et al. (2002). Age, sex and laterality effects on cerebral glucose metabolism in healthy adults. Psychiatry Res 114: 23-37.
184. Wu Z, Huang X, Feng Y, Handschin C, Gullicksen PS, Bare O, et al. (2006). Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1alpha transcription and mitochondrial biogenesis in muscle cells. Proc Natl Acad Sci U S A 103: 14379-14384.
185. Yamaguchi R, Janssen E, Perkins G, Ellisman M, Kitada S, Reed JC, (2011). Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy. PLoS ONE 6: e24102.
186. Youle RJ, Narendra DP, (2011). Mechanisms of mitophagy. Nat Rev Mol Cell Biol 12: 9-14.
187. Young AJ, Johnson S, Steffens DC, Doraiswamy PM, (2007). Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr 12: 62-68.
188. Zemke D, Azhar S, Majid A, (2007). The mTOR pathway as a potential target for the development of therapies against neurological disease. Drug News Perspect 20: 495-499.
189. Zhu X, Perry G, Smith MA, Wang X, (2013). Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 33 (Suppl. 1): S253-S262.